Peer-influenced content. Sources you trust. No registration required. This is HCN.

Practical NeurologyGantenerumab Did Not Slow Clinical Decline as Expected in Individuals with Early Alzheimer Disease

Gantenerumab treatment generated a slowing of clinical decline from baseline score on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), but at levels that did not reach statistical significance. The relative reduction in clinical decline was 8% in GRADUATE I and 6% in GRADUATE II compared with placebo.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form